313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

• Xiaoyu Zhang,
• Sanjeev Kaul,
• Paul Moore,
• Jason Luke,
• Bartosz Chmielowski,
• Hedy Kindler,
• Francine Chen,
• George Blumenschein,
• Erika Hamilton,
• Shakeela Bahadur,
• Cesar Santa-Maria,
• Janine Koucheki,
• Jichao Sun,
• John Muth,
• Patrick Kaminker,
• Bradley Sumrow

Affiliations

Xiaoyu Zhang

Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China

Sanjeev Kaul

10Bio-ClinPharm Consulting, LLC, Cranbury, NJ, USA

Paul Moore

Aff3 grid.421076.6MacroGenics, Inc., Rockville Rockville MD United States

Jason Luke

Aff615 grid.170205.10000000419367822University of Chicago Chicago IL USA

Bartosz Chmielowski

Aff7 0000 0000 9632 6718grid.19006.3eJonsson Comprehensive Medical CenterUniversity of California Los Angeles, 10945 Le Conte Ave #2339 Los Angeles CA USA

Hedy Kindler

Aff4 grid.170205.10000000419367822The University of Chicago Chicago IL USA

Francine Chen

Aff6 grid.421076.60000 0004 0432 6278MacroGenics San Francisco CA USA

George Blumenschein

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Erika Hamilton

3Sarah Cannon Research Institute, Nashville, TN, USA

Shakeela Bahadur

7Banner MD Anderson Cancer Center, Gilbert, AZ, USA

Cesar Santa-Maria

8Sidney Kimmel Comprehensive Cancer Ctr, Baltimore, MD, USA

Janine Koucheki

9MacroGenics, Inc., Rockville, MD, USA

Jichao Sun

9MacroGenics, Inc., Rockville, MD, USA

John Muth

9MacroGenics, Inc., Rockville, MD, USA

Patrick Kaminker

9MacroGenics, Inc., Rockville, MD, USA

Bradley Sumrow

9MacroGenics, Inc., Rockville, MD, USA